Scholarlink

<p>Robotic-assisted surgery (RAS) in India remains limited by cost and accessibility. The SSI Mantra™ is an indigenous system that was developed to address these barriers. This retrospective cohort study (IDEAL Stage 2b) analyzed 3,694 consecutive RAS cases across 78 centers in India (Feb 2023–Apr 2025) to assess the feasibility, safety, and learning curves of the system. Patient demographics, intraoperative metrics, and outcomes were extracted from prospectively maintained databases. Surgeons were grouped by experience quartiles (Q1–Q4) to analyze console time, conversions, and length of hospital stay (LOS) using descriptive and adjusted regression models. Learning curves were evaluated using continuous cumulative sum (CUSUM) analysis. Mean age was 51 years ± 15.8, with 57.2% being male. Mean blood loss was 75.4&#xa0;ml ± 52.6; intraoperative adverse events (AEs) occurred in 0.6% of cases. Median LOS was 3 days (IQR: 2–4). Overall conversion rate was 4.1% (95% CI: 3.6–5.0%), varying by the procedure type and surgeon’s experience. More experienced surgeons (Q4) had shorter adjusted console times (154 vs. 169.6&#xa0;min, <i>p</i> &lt; 0.001) and lower conversion rates. Longer console time was linked to lower conversion odds. LOS increased with conversions but was more stable for experienced surgeons. CUSUM charts showed clear learning curve differences. No device-related AEs were reported. These results suggest that SSI Mantra™ is feasible, with minimal intraoperative AEs for diverse and complex procedures, with consistent performance across centers and specialties. Its lower capital cost may expand RAS access in India. Surgeon experiences improved efficiency and outcomes, supporting structured training. Long-term outcomes and comparative effectiveness warrant further study.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world performance of the SSI Mantra™ robotic system: a multi-centric multi-specialty study evaluating its safety and surgical applications

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月3日

查看全文
  • Somashekhar SP,
  • Medha Sugara,
  • Kushal Agrawal,
  • Sudhir Kumar Rawal,
  • Amitabh Singh,
  • Magan Mehrotra,
  • Raj Gajbhiye,
  • Chandramohan Vaddi,
  • Srikarthik Voleti,
  • Leena Mehrotra,
  • Ganesh Gorthi,
  • Manjiri Somashekhar,
  • Nitin Kumar Rajput

摘要

Robotic-assisted surgery (RAS) in India remains limited by cost and accessibility. The SSI Mantra™ is an indigenous system that was developed to address these barriers. This retrospective cohort study (IDEAL Stage 2b) analyzed 3,694 consecutive RAS cases across 78 centers in India (Feb 2023–Apr 2025) to assess the feasibility, safety, and learning curves of the system. Patient demographics, intraoperative metrics, and outcomes were extracted from prospectively maintained databases. Surgeons were grouped by experience quartiles (Q1–Q4) to analyze console time, conversions, and length of hospital stay (LOS) using descriptive and adjusted regression models. Learning curves were evaluated using continuous cumulative sum (CUSUM) analysis. Mean age was 51 years ± 15.8, with 57.2% being male. Mean blood loss was 75.4 ml ± 52.6; intraoperative adverse events (AEs) occurred in 0.6% of cases. Median LOS was 3 days (IQR: 2–4). Overall conversion rate was 4.1% (95% CI: 3.6–5.0%), varying by the procedure type and surgeon’s experience. More experienced surgeons (Q4) had shorter adjusted console times (154 vs. 169.6 min, p < 0.001) and lower conversion rates. Longer console time was linked to lower conversion odds. LOS increased with conversions but was more stable for experienced surgeons. CUSUM charts showed clear learning curve differences. No device-related AEs were reported. These results suggest that SSI Mantra™ is feasible, with minimal intraoperative AEs for diverse and complex procedures, with consistent performance across centers and specialties. Its lower capital cost may expand RAS access in India. Surgeon experiences improved efficiency and outcomes, supporting structured training. Long-term outcomes and comparative effectiveness warrant further study.